acetylcholine,alzheimer's

SIB-1553A hydrochloride is an orally available, selective nicotinic acetylcholine receptor agonist and a selective neuronal nAChR ligand.SIB-1553A hydrochloride enhances cognition and may be useful in the study of Alzheimer's disease and cognitive impairment.

SIB 1553A is an orally available and selective agonist of nicotinic acetylcholine receptors (nAChRs), which are subtype-selective ligands for nicotinic acetylcholine receptors.SIB-1553A is a cognitive enhancer that may be used in the study of neurodegenerative-related diseases such as Alzheimer's disease.

JNJ-39393406 is an α7 nicotinic acetylcholine receptor positive allosteric modulator for the study of tobacco dependence and Alzheimer's disease.

SCH 57790 is a novel and selective muscarinic M(2) receptor antagonist that releases acetylcholine and enhances cognition in experimental animals for the treatment of Alzheimer's disease.

Galanthamine hydrobromide (Galantamine hydrobromide), a long-acting and centrally active AChE inhibitor (IC50:410 nM), is an allosteric potentiator at neuronal nicotinic ACh receptors.

sn-Glycero-3-phosphocholine (Choline glycerophosphate) is a natural choline compound found in the brain and in milk. It is also a parasympathomimetic acetylcholine precursor which may have a potential for the treatment of Alzheimer's disease and dementia. sn-Glycero-3-phosphocholine rapidly delivers choline to the brain across the blood–brain barrier and is a biosynthetic precursor of the acetylcholine neurotransmitter. It is a non-prescription drug in most countries due to its Generally Recognised As Safe (GRAS) status [1]. Studies have investigated its efficacy for cognitive disorders including stroke and Alzheimer's disease. An Italian multicentre clinical trial on 2, 044 patients suffering from recent stroke were supplied Glycerylphosphorylcholine in doses of 1, 000 mg/day for 28 days and 400 mg three times per day for the five ensuing months. The trial confirmed the therapeutic role of alpha-GPC on the cognitive recovery of patients based on four measurement scales, three of which reached statistical significance [2].

Arecoline is a natural alkaloid derived from areca nut in the palm family and is a potent nicotine and partial agonist of muscarinic acetylcholine receptors. Arecoline has anti-anxiety and anti-parasitic activity, can induce oxidative stress and can be used to study Alzheimer's disease and Alzheimer's disease.

Nebracetam hydrochloride (WEB 1881 FU hydrochloride) is an agonist nootropic M1-muscarinic. Nebracetam hydrochloride induces a rise of intracellular Ca2+ concentration. Nebracetam hydrochloride exhibits an EC50 of 1.59 mM for elevating [Ca2+]i.

VU0357017 hydrochloride (ML071 hydrochloride) is highly selective M1 agonists act at an allosteric site to activate the receptor (EC50: 477 ± 172 nM; Pec50: 6.37 ± 0.15).

nAChR agonist 1 (DUN71755) is a brain-permeable and orally efficacious positive allosteric α7 nicotinic acetylcholine receptor (α7 nAChR)modulator.

Dicyclomine hydrochloride is a muscarinic antagonist used as an antispasmodic and in urinary incontinence.

Lecozotan (SRA-333) is a potent and selective 5-HT antagonist developed for Alzheimer's disease treatment. This compound significantly increases the release of glutamate and acetylcholine in the hippocampus and dentate gyrus areas upon potassium ion stimulation, exhibiting cognitive enhancement properties. Long-term use of Lecozotan does not lead to tolerance or dysfunction of the 5-HT(1A) receptor, demonstrating its stable pharmacological properties. Additionally, acute administration can improve learning and memory abilities in rats without affecting their anxiety levels or behavior depression.

AChE-IN-90 (Compound 5b) is an orally active, brain-penetrant, and potent acetylcholinesterase (AChE) inhibitor with an IC50 value of 0.023 μM against human AChE. It shows lower selectivity for butyrylcholinesterase (BuChE) with an IC50 of 1.8 μM. AChE-IN-90 increases acetylcholine levels in synaptic clefts and holds potential for research in neurodegenerative diseases such as Alzheimer's disease.

AChE-IN-92 (Compound L4R1-3) is a highly selective acetylcholinesterase (AChE) inhibitor with an IC50 of 4.6 nM. It effectively prevents the hydrolysis of acetylcholine, thereby increasing its levels in the synaptic cleft. AChE-IN-92 holds potential for research in Alzheimer's disease (AD).

BChE-IN-44 is a potent and highly selective butyrylcholinesterase (BChE) inhibitor that can penetrate the blood-brain barrier, demonstrated by [equineBChEIC50= 18.00 pM, humanBChEIC50= 1.50 nM]. BChE-IN-44 offers neuroprotective effects against Aβ1-42-induced damage models and halts the self-aggregation of Aβ1-42. It reduces levels of inflammatory factors (NO, IL-6, and TNF-α) in BV2 cells induced by lipopolysaccharides. Additionally, BChE-IN-44 significantly ameliorates cognitive impairment caused by scopolamine. It also regulates BChE and acetylcholine levels in the hippocampus of mice. BChE-IN-44 is applicable for Alzheimer's disease (AD) research.

T 588 is an orally active neuroprotective agent that enhances acetylcholine release in the frontal cortex and hippocampus, thereby improving cognitive dysfunction. It safeguards cerebellar granule cells from glutamate-induced neurotoxicity and is applicable in neurological research, including studies on Alzheimer's disease.

VU6052254, a derivative of VU0467319, is a selective, potent, orally active positive allosteric modulator of the muscarinic M1 acetylcholine receptor (mAChR1) that can cross the blood-brain barrier, with an EC50 value of 59 nM. It shows no activity on M2-5 receptors (EC50 value greater than 30 μM). VU6052254 enhances memory and reverses scopolamine-induced cognitive deficits, with a minimum effective dose of 1 mg/kg. This compound is applicable in research on neurological disorders such as Alzheimer's disease.

Eseroline is a potent μ-opioid receptor agonist and a hydrolytic metabolite of Physostigmine. It serves as a selective and competitive acetylcholinesterase (AChE) inhibitor, with inhibition constants (Ki) of 0.1 μM for AChE and 200 μM for butyrylcholinesterase (BuChE). Eseroline acts as an allosteric potentiating ligand of nicotinic acetylcholine receptors (nAChR-APL), enhancing Ach-induced nAChR signaling without directly activating the receptor. The compound is neurotoxic, causing cellular membrane damage (LDH leakage) and energy metabolism collapse (ATP depletion). Additionally, Eseroline can be utilized in Alzheimer's disease research.

BChE-IN-46 is a selective BChE inhibitor with the ability to penetrate the blood-brain barrier [eqBChE IC50 = 7.44 × 10^-5 μM, SI > 270,000, hBChE IC50 = 1.48 × 10^-3 μM]. It also exhibits COX-2 inhibitory activity (IC50 = 0.11 μM). BChE-IN-46 may offer neuroprotective effects, enhance acetylcholine levels, and improve cognitive dysfunction, anxiety, as well as learning and memory deficits. It is a potential candidate for the development of anti-Alzheimer's disease drugs.

Physostigmine is an alkaloid extracted from the poison bean (Physostigma venenosum) and acts as a reversible acetylcholinesterase (AChE) inhibitor. Physostigmine inhibits the action of acetylcholinesterase, increasing acetylcholine levels, and thus serves as an antidote for anticholinergic poisoning. Physostigmine crosses the blood-brain barrier and stimulates central cholinergic neurotransmission. Physostigmine can reverse memory deficits in transgenic mice with Alzheimer's disease.

BChE-IN-47 (Compound 13) is a selective butyrylcholinesterase (BChE) inhibitor with an IC50 value of 0.045 μM. By selectively inhibiting BChE, BChE-IN-47 enhances acetylcholine levels in the brain, thereby improving cognitive function. This compound is applicable in Alzheimer's disease research.

p-F-HHSiD (p-Fluorohexahydrosiladifenidol) is a potent and selective antagonist of the M3 muscarinic acetylcholine receptor (M3mAChR). Additionally, it exhibits antagonistic effects on other M receptor subtypes and the α1-adrenoceptor (alpha1-adrenoceptor). This compound is applicable in research concerning cancer, metabolic disorders, neurological diseases, and cardiovascular conditions, including studies on colon cancer, Alzheimer's disease, and diabetes.

SEN12333 is an α7 nicotinic acetylcholine receptor (nAChR) agonist

Zanapezil (TAK-147) is a powerful and selective inhibitor of acetylcholine esterase (AChE). It demonstrates significant and reversible inhibition of AChE activity in rat cerebral cortex homogenates (IC50 = 51.2 nM). Furthermore, Zanapezil exhibits moderate inhibition of muscarinic M1 and M2 receptor binding with Ki values of 234 and 340 nM, respectively. This compound holds promise for the investigation of the initial stages of Alzheimer's disease (AD).